University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Won Kim, M.D.

Medical oncologist


Prostate Cancer Center
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Urologic Surgery and Oncology
1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-7171
Fax: (415) 514-6195

Hours: Monday to Friday
8 a.m. – 5 p.m.

More about Won Kim


Weill Medical College of Cornell University 2007


New York Presbyterian Hospital-Weill Cornell 2010


University of California, San Francisco 2012

Selected Research and Publications

  1. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76.
  2. Kim W, Ryan CJ. Quo vadis: Advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies. Cancer. 2015 Feb 1; 121(3):361-71.
  3. Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):292-9.
  4. Kim W, Ryan CJ. Friend or foe: the bifunctional role of steroid hormones in prostate cancer. Oncology (Williston Park). 2014 May; 28(5):408, 410.
  5. Kim W, Wilton J, Zhang L, Lin AM, Fong L, Hsieh AC, Friedlander T, Aggarwal R, Morse A, Bozeman J, Weinberg V, Molina A, Fetterly G, Mohler J, Szmulewitz RZ, Small EJ, and Ryan CJ. Activity of abiraterone acetate in metastatic castration-resistant prostate cancer patients previously treated with ketoconazole: a prospective phase II study from the Prostate Cancer Clinical Trials Consortium. J Clin Oncol. 2014; 32(suppl 4):abstr 53.
  6. Van Allen EM, Foye A, Wagle N, Kim W, Carter SL, McKenna A, Simko JP, Garraway LA, Febbo PG. Successful whole-exome sequencing from a prostate cancer bone metastasis biopsy. Prostate Cancer Prostatic Dis. 2014 Mar; 17(1):23-7.
  7. Kim W, Febbo PG. The current and future role of sequenced-based analysis in prostate cancer tretament. Personalized Medicine. 2013; 10(3):257-273.
  8. Kim W, Febbo PG. RNA transcription and translation. In Stadler WM ed. Cancer Biology Review: A Case-Based Approach. 2013.
  9. Kim W, Foye A, Bengtsson H, Kim H, Taylor B, Pourmand N, Febbo PG. Feasibility of RNA sequencing to detect TMPRSS2:ERG fusions following laser capture microdissection of prostate cancer. J Clin Oncol. 2013; 31(suppl 6):abstr 76.
  10. Kim W, Ryan CJ. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer. Curr Treat Options Oncol. 2012 Jun; 13(2):189-200.
  11. Gelbman BD, Cham MD, Kim W, Libby DM, Smith JP, Port JL, Altorki NK, Henschke CI, Yankelevitz DF. Radiographic and clinical characterization of false negative results from CT-guided needle biopsies of lung nodules. J Thorac Oncol. 2012 May; 7(5):815-20.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.